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Dyskeratosis congenita (DC) is a rare genetic disorder characterized by a classic triad of physical findings consisting of nail dystrophy of the hands and/or feet, mucosal leukoplakia and reticular pigmentation of the skin, most commonly on the head, neck and trunk. 1 Bone marrow failure along with pulmonary complications and malignancies are all common causes of premature death in patients with DC as well as a myriad of other abnormalities. 2, 3 Hematopoietic stem cell transplantation (HSCT) with fully myeloablative regimens has historically been the only curative treatment. 2, 3 Attempts at reducing morbidity and mortality post HSCT with reduced intensity conditioning regimens instead of myeloablative regimens have been reported, and over the past decade, experience treating DC associated marrow failure with reduced intensity HSCT has increased. 4 Here we report the HSCT course of two patients with successful restoration of hematopoiesis following reduced intensity conditioning and unrelated cord blood transplant (see Table 1 for patient descriptions).
Patient 1
Patient 1 is a 9-year-old white male with a history of macrocephaly. He was diagnosed with severe aplastic anemia at the age of 5 years. Approximately 1.5 years before this diagnosis, he had an event where the tip of his tongue became white, jagged and painful. He presented to his primary care physician where it was treated as a viral infection. Concomitantly, circular flat scalp lesions appeared on his head followed by hair loss and crusted patches. He also had a history of easy bruising for 18 months and dysplastic nails. He was hospitalized multiple times for immunosuppressant therapy with cyclosporine and antithymocyte globulin (ATG) over the previous year. A bone marrow biopsy was obtained and showed markedly hypocellular marrow with cellularity o10% on average and tri-lineage hypoplasia with no evidence of malignancy. Telomere length testing was done and shown to be less than the first percentile in all lymphocyte subset and granulocytes, supporting a diagnosis of DC. Genetic testing revealed heterozygosity for R282H mutation in the TINF2 gene. He was referred for allogeneic stem cell transplantation. He did not have a fully matched sibling and an extensive unrelated donor search did not reveal a fully matched unrelated donor nor a good size, well matched umbilical cord. He received 2 partially matched unrelated umbilical cords; 4/6 with a total neutrophil count (TNC) 9. WBC with an ANC 4500 x 3 days on day +30 post transplant. He was discharged from the hospital on day +34 with no significant toxicity and was transfusion independent. On day +45 after transplant, chimerism evaluation showed 100% donor. The patient was weaned off immunosuppressant by 6 months post transplant. He continues to have normal blood counts over 43 months post transplant with full donor chimerism. He never developed acute or chronic GvHD (cGvHD) or other transplant-related toxicities.
Patient 2
Patient 2 is a 10-year-old white male with a history of developmental delay, particularly speech and motor delays. At 2 years of age, he began to have excessive bruising. A complete blood count (CBC) was obtained that showed a platelet count of 75 000 which prompted a diagnosis of idiopathic thrombocytopenic purpura as the remainder of the CBC was normal. He was treated with IV Ig with no increase in platelet count. At 3.5 years of age, a bone marrow biopsy performed that confirmed the diagnosis of aplastic anemia. His bone marrow was negative for Fanconi's Anemia with normal cytogenetics. Progressive cytopenias were noted soon after the marrow exam with hemoglobin decreasing to 7 gm/dL and his WBC to 2.0 with an ANC o 500. A follow up bone marrow biopsy revealed a cellularity of 5% with normal cytogenetics. Repeat testing for Fanconi's anemia was negative, there was no morphologic or cytogenetic evidence of myelodysplasia, and paroxysmal nocturnal hematuria testing was negative. However, testing for telomere length by flow cytometry with FISH was positive for short telomere length in all subsets of lymphocytes (T cells, B cells and natural killer cells) below the first percentile. TERT and TERC mutation analysis was obtained that showed a p.H525Q mutation in the TERT gene. A diagnosis of DC was established and he was referred for allogeneic stem cell transplantation. He received a total of 2 packed RBCs transfusions, 6 platelet transfusions, and was hospitalized a total of three times for fever and neutropenia requiring transfusions before transplant. He had no full siblings and an extensive unrelated donor search did not reveal any fully matched unrelated donors. A cord blood search revealed a 5/6 matched unrelated cord with a TNC of 7.85 x 10 7 . He therefore received a 5/6 matched cord blood transplant. His reduced intensity conditioning regimen consisted of cyclophosphomide 50 mg/kg x 1, fludarabine 40 mg/ m 2 x 5, alemtuzumab 0.2 mg/kg x 5, and TBI 200cGy). GvHD prophylaxis consisted of tacrolimus and mycophenolate mofetil. Neutrophil engraftment with an ANC 4500 x 3 days was on day +34 post transplant. Overall, he received a total of 10 platelet transfusions and five packed RBC transfusions during his posttransplant course and has been transfusion independent with full donor chimerism for 34 months post his transplant. His initial transplant course was complicated by Human Herpes Virus six reactivation which was treated with Foscarnet and cecal pneumotosis which was treated with cefipime and metronidazole.
He developed stage three acute GvHD of the skin, but no other organ involvement, and was successfully treated with a short course of systemic and topical steroids. The patient showed full donor chimerism since~4 months post transplant and is transfusion independent, alive and well 35 months post transplant.
DC can be inherited by X-linked, autosomal dominant and autosomal recessive mechanisms. 2 The main culprit of this disease is the gene mutation and subsequent dysfunction of proteins important to the maintenance of the telomere length, which lead to the clinical manifestations of the disease. 5, 6 The principal cause of death in DC patients is bone marrow failure and complications of bone marrow transplantation such as pulmonary fibrosis and hematological abnormalities. 7 In patients with bone marrow failure syndromes, bone marrow-derived stem cells are the traditionally preferred source of hematopoietic stem cells. Increased mortality related to cGvHD with PBSCs provided the rationale for this preference. The use of umbilical cord blood as a source has been limited due to concerns of graft rejection or graft failure. 8 However, several reports suggest that compared with bone marrow transplantation, umbilical cord transplantation has a lower incidence of acute and cGvHD. To overcome the risk of rejection in our two patients, a good cell dose of the unrelated umbilical cord blood transplantation was used either from a single cord or from the combination of double cords. Telemeropathy as a result of defective DNA repair in these cells related to telomerase dysfunction and resultant early cell senescence in patients with DC is likely responsible for the severe multi-organ toxicity and death that can be related to myeloablative transplant conditioning regimens. 2 Several reports have shown that despite being a bone marrow failure syndrome, the use of reduced intensity conditioning preparative regimens are safer, carries less morbidity and has no increased risk of graft failure or rejection. 1, 8, [9] [10] [11] [12] [13] In some of these reports, however, the ex vivo T-cell depletion was with ATG and in general, the source of stem cells was nonumbilical cord blood stem cells. In both patients in this report, ATG was replaced with alemtuzumab, which has more in-depth lymphocyte depletion with the hope that this will decrease any chance for rejection. It has been reported that related umbilical cord transplantation results in excellent outcomes compared with unrelated cord blood, but 'increasing cell dose and better HLA matching might provide better results in unrelated umbilical cord blood transplantation'. 8 Despite improved transplant outcomes in many other bone marrow failure disorders, DC patients still have a lower 5-year post-transplantation survival probability, comparatively. 3 Our patients have not yet reached the 5-year mark, but had no major transplant toxicities and continue to show full donor chimerism 3+ years out. Neither of the two patients discussed in this case report had available matched siblings or fully matched unrelated donors, therefore in both cases, partially matched unrelated cord blood units were used. Further study of RIC regimens and the type of T-cell depletion for patients with DC and other bone marrow failure syndromes are warranted to determine the least toxic and most efficacious regimens, likely tailored to a hematopoietic stem cell source. Letter to the Editor
